



Value Proposition

MEMbrane Base Automated Syringe is an innovative medical device for the slow administration of medicinal solutions by injection without external energy at a controlled rate:

- Continuous administration flowrate selection
- Locking system of the plunger position
- Clear indication of the loaded volume

Product description & Innovation


MEMBAS is a portable medical device enabling the slow administration of drugs under safe conditions thanks to a locking system of the plunger.

Self sufficient device for an automated and controlled injection of liquid:

- No need of external energy
- Operating without any human intervention
- One single device for loading and ejection of solution to be injected


Easily customizable according to the application:

- Slow modes of administration allowed (few sec to few hours)
- Large range of possible volumes (few mL to hundreds of mL)
- Large range of possible flow rates (1mL/sec to < 0,01 mL/sec)



Market

- Global **ambulatory infusion pumps market: USD 734.7 million in 2020** with an expected growth at a CAGR of 2.2% from 2025
-> **USD 915.5 million in 2030.**
- Hospitals market = **59,6%** of the global market / Home healthcare market = growth at **CAGR of 2,9%** during 2020/2025



Diverse range of applications such as

- Administration of medicines in **emergency situations**
- Administration of **antibiotics for outpatient**
- Administration of **commun medicines in LI/LMI* countries public hospitals**
- **Nasogastric feeding**

Stage of progress

- The project, supported by SATT Conectus which invested in **a maturation program**, aims to:
 - Confirm a **technico-economic positioning** of the MEMBAS medical device
 - Provide a **TRL6 Proof Of Concept**
 - Achieve **preclinical trials**
 - Transfer the technology to an **industrial partner for clinical trials, CE and/or FDA certification, industrialization and commercialization**

SECTOR

MEDECH

FIELD OF ACTIVITY

surgery, cell therapy, immunotherapy, drug delivery

TEAM/KEY PARTNERS

Dr. Valeriy LUCHNIKOV

in the **IS2M**, a French laboratory bringing together researchers of the **University of Haute-Alsace** and the **CNRS**



IP STATUS

MEMBAS is an innovative technology for which an EP priority (13/04/2022) & PCT extension (13/04/2023) patent application have been filed.



CONTACT

Sébastien ZUIN
Business Developer MedTech
Conectus
+ 33 (0)6 19 16 16 87
Sebastien.zuin@satt.conectus.fr

We offer an exclusive licensing option agreement including	We expect a co-development effort including
<ul style="list-style-type: none"> - Joint development - Right of first refusal - IP managed by Conectus in accordance with licensee strategy - Commercial use on defined fields/applications and territories 	<ul style="list-style-type: none"> - A Technical support to reach the development target: successful preclinical tests - Financial compensation (to be defined together) deductible from future licensee fees